Table 2 Comparison of demographics and characteristics of hospital stay between critical clusters 1 and 2 of Discovery cohort with the validation cohort
From: Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity
Variables | Entries | Cluster 1 + 2—Discovery | Validation (entire cohort) | p |
|---|---|---|---|---|
N | 87 | 76 | ||
Age (mean (SD)) | 68.8 (13.72) | 59.42 (13.75) | <0.001 | |
Sex (male (%)) | 52 (59.8%) | 60 (78.9) | 0.0084 | |
Max respiratory support throughout hospital stay | ||||
No O2 | 15 (17.2%) | 0 (0%) | <0.001 | |
NC/HFNC | 13 (14.9%) | 0 (0%) | <0.001 | |
NIV | 16 (18.4%) | 25 (32.9%) | 0.033 | |
ETI | 42 (48.3%) | 49 (65.3%) | 0.038 | |
ECMO | 1 (1.2%) | 2 (2.6%) | 0.48 | |
ICU admission | 56 (64.4%) | 76 (100%) | <0.001 | |
Days in ICU (mean (SD)) | 20.5 (20.55) | 14.54 (10.04) | 0.023 | |
Metabolic risk factors | ||||
Any metabolic risk factor | 63 (72.4%) | 50 (75.8%) | 0.36 | |
Obese (%) | 17 (19.5%) | 27 (40.9%) | 0.022 | |
Hypertension (%) | 56 (64.3%) | 40 (52.6%) | 0.13 | |
Diabetes (%) | 34 (39.1%) | 21 (27.6%) | 0.12 | |
Chronic diseases | ||||
One or more (%) | 59 (67.8%) | 38 (50.7%) | 0.12 | |
Chronic Kidney Disease (%) | 22 (25.3%) | 17 (22.4%) | 0.66 | |
Heart Failure (%) | 22 (25.3%) | 3 (3.9%) | <0.001 | |
Respiratory Disease (%) | 20 (23.0%) | 19 (25.0%) | 0.76 | |
Liver Disease (%) | 12 (13.8%) | 0 (0%) | <0.001 | |
Immunosuppressed (%) | 10 (11.5%) | 10 (13.3%) | 0.75 | |
Malignancy (%) | 12 (13.8%) | 3 (3.9%) | 0.03 | |
HIV (%) | 3 (3.4%) | 0 (0%) | 0.10 | |
Neurological disorder (%) | 11 (12.6%) | 4 (5.3%) | 0.10 | |
Risk factors metabolic or chronic | ||||
One or more (%) | 74 (85.1%) | 58 (89.2%) | 0.16 | |
Outcome | ||||
Fatality DSO60 (%) | 24 (27.8%) | 18 (23.7%) | 0.57 | |
